Neil Mehta, MD


Dr. Neil Mehta is a gastroenterologist and transplant hepatologist. He is interested in liver cancer treatment, particularly related to liver transplants and has contributed to important publications in this area. His other research interests include outcomes for liver transplantation and cardiac iron overload in chronic liver disease. He frequently lectures in the community and at the university on these subjects, including delivering the UCSF medical student liver lectures during the metabolism and nutrition block.

Mehta is an assistant clinical professor of medicine in the UCSF School of Medicine where he supervises the training of medicine residents and both gastroenterology and liver transplant fellows. He earned a medical degree at UCSF and completed internal medicine residency at the University of Pennsylvania. He then completed fellowships in both gastroenterology and liver transplantation at UCSF.


Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Liver Transplant Program
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1888
Fax: (415) 353-8917

Hours: Pre-Liver Transplant Clinic Monday, Tuesday, Wednesday 7 a.m. – 12 p.m.
Hours: Post-Liver Transplant Clinic Tuesday 8 a.m. – 12 p.m., Thursday 1-4 p.m.

Board Certification

Gastroenterology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Transplant Hepatology, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Neil Mehta


University of California San Francisco School of Medicine 2006


Hospital of the University of Pennsylvania 2009


UCSF Medical Center 2013

Selected Research and Publications

  1. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of Hepatocellular Carcinoma in Patients Receiving no Loco-regional Therapy Prior to Liver Transplant: An Analysis of the OPTN Explant Pathology Form. Clin Transplant. 2017 Sep 07.
  2. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 Sep; 101(9):2071-2078.
  3. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 Aug; 23(8):1015-1022.
  4. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368.
  5. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500.
  6. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 Dec; 151(6):1062-1065.
  7. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 Oct; 64(4):1178-88.
  8. Mehta N, Yao FY. Reply. Liver Transpl. 2016 Aug; 22(8):1164-5.
  9. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9.
  10. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4.
  11. Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8.
  12. Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7.
  13. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87.
  14. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4.
  15. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77.
  16. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9.
  17. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8.
  18. Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285.
  19. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51.
  20. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.